News
ATHE
1.180
-3.25%
-0.040
Alterity Therapeutics announces new publication on ATH434
TipRanks · 2d ago
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
Barchart · 2d ago
Weekly Report: what happened at ATHE last week (1028-1101)?
Weekly Report · 4d ago
Alterity Therapeutics reports cash balance of A$9.28M as of September 30
TipRanks · 10/31 11:47
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
Barchart · 10/31 06:35
Weekly Report: what happened at ATHE last week (1021-1025)?
Weekly Report · 10/28 11:15
Weekly Report: what happened at ATHE last week (1014-1018)?
Weekly Report · 10/21 11:11
Alterity Therapeutics to Present at Healthcare Summit
TipRanks · 10/15 12:27
Weekly Report: what happened at ATHE last week (1007-1011)?
Weekly Report · 10/14 11:39
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
Barchart · 10/14 06:35
Alterity Therapeutics presents data on neuroprotection of ATH434
TipRanks · 10/11 11:41
Alterity Therapeutics Announced New Data Related To ATH434 Were Presented At The Society For Neuroscience 2024-Filing
Benzinga · 10/11 10:11
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
Barchart · 10/11 06:35
Weekly Report: what happened at ATHE last week (0930-1004)?
Weekly Report · 10/07 11:28
Alterity Therapeutics presents data on ATH434 at MDS Congress
TipRanks · 10/02 11:45
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
Barchart · 10/02 06:35
Alterity Therapeutics appoints Abby Macnish Niven as CFO
TipRanks · 09/30 11:45
Alterity Therapeutics Tapped Macnish Niven As CFO, Succeeding Phillip Hains
Benzinga · 09/30 11:36
ALTERITY THERAPEUTICS APPOINTS ABBY MACNISH NIVEN AS CHIEF FINANCIAL OFFICER
Reuters · 09/30 11:35
Weekly Report: what happened at ATHE last week (0923-0927)?
Weekly Report · 09/30 11:21
More
Webull provides a variety of real-time ATHE stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.